Clinical Research Directory
Browse clinical research sites, groups, and studies.
China Gender-affirming Hormone Therapy Study
Sponsor: Peking University Third Hospital
Summary
Data about transgender medical care, especially the gender-affirming hormone therapy (GAHT) is extremely insufficient in China. Few evidence exists in the physical and psychological effects of the hormonal treatment in Chinese transgender population. CGAHT is designed to describe the social and mental condition of transgender people who are seeking for formal GAHT, and to investigate the physical and psychological effects of GAHT on this population in China.
Official title: China Gender-affirming Hormone Therapy Study in Transgender Men and Women
Key Details
Gender
All
Age Range
18 Years - 40 Years
Study Type
OBSERVATIONAL
Enrollment
240
Start Date
2022-04-16
Completion Date
2028-12-31
Last Updated
2024-11-07
Healthy Volunteers
Yes
Conditions
Interventions
GAHT for transgender men
Testosterone undecanoate
GAHT for transgender women
Estradiol and antiandrogens (Spironolactone or Cyproterone acetate)
Locations (1)
Peking University Third Hospital
Beijing, Beijing Municipality, China